1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Novo Nordisk Lowers Some Insulin List Prices, Following Lilly’s Lead

 
• By Jessica Merrill

The company will lower the US list price of Levemir, NovoLog and certain other branded insulins by 65-75% and will also lower some unbranded insulin prices effective January 2024. Tresiba is not included.

scissors
Novo Nordisk moves on US insulin list price cuts • Source: Shutterstock

Novo Nordisk A/S announced it will cut US list prices for several of its insulin products for diabetes, following a similar move just two weeks ago by its big rival Eli Lilly and Company. Novo plans to lower the US list price of its long-acting basal insulin Levemir (insulin detemir), as well as short-acting and pre-mix insulins including Novolin, NovoLog and NovoLog Mix 70/30 by 65%-75%, the firm said on 14 March.

Tresiba (insulin degludec) – Novo Nordisk’s newer ultra-long-acting insulin that launched in the US in 2016 – will not be included in the price cutting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.